Medical Marijuana, Inc. Subsidiary Kannaway® Unveils Anticipated New Products in U.S. and Europe at 2021 Focus Virtual Kickoff Event
Medical Marijuana, Inc.
Medical Marijuana, Inc. Subsidiary Kannaway® Unveils Anticipated New Products in U.S. and Europe
SAN DIEGO, CA, Jan. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has launched several new products in the U.S. and Europe as part of the Company’s 2021 Focus Virtual Kickoff Event. These newly launched products include the Company’s cannabigerol (CBG) tincture in the U.S. and a brand new Green Hemp (cannabidiol) CBD Oil in Europe
“Cannabis continues to grow in global acceptance and the future of the industry is going to lie with those who understand the potential benefits of the entire hemp plant in addition to CBD. That’s why we’re looking forward to sharing these new products with consumers in the U.S. and Europe as we extract the nutrients straight from the hemp plant and deliver it to homes around the world,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We have received a very positive response to our CBG product from the European market and are confident consumers in the U.S. will love it as well.”
In December 2020, the Company received a warm welcome into the European CBG market. In the U.S., Kannaway® has officially launched its Pure CBG tincture. Each one-ounce bottle of the tincture infuses 1,000 mg of CBG isolate into multi-chain triglyceride (MCT) oil for increased absorption.
Kannaway®’s Green Hemp Oil, now available to consumers in Europe, combines organic hemp seed oil with raw hemp oil to bring the nutrition of broad-spectrum cannabinoids as they are found in a live hemp plant right to your home. Each one-ounce bottle contains 500 mg of CBD and its acidic precursor CBDA.
To learn more about these products and/or purchase them, please visit https://kannaway.com/shop.html.
About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
Attachment
